BRAF and melanoma: We show that BI-78D3 has antitumor activity in BRAF/MEK inhibitor-naïve and BRAF/MEK inhibitor-resistant melanoma cells containing a BRAF mutation, demonstrating its obvious potential to overcome acquired resistance to BRAF and MEK inhibitors.